<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270370</url>
  </required_header>
  <id_info>
    <org_study_id>17537</org_study_id>
    <secondary_id>J2M-MC-GZKA</secondary_id>
    <nct_id>NCT04270370</nct_id>
  </id_info>
  <brief_title>A Study of LY3478045 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single-and Multiple Ascending Doses of LY3478045in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study in healthy participants is to learn more about the safety of
      LY3478045 and any side effects that might be associated with it. The study will also measure
      how much LY3478045 gets into the bloodstream and how long it takes the body to get rid of it.

      This study has two parts: Part A (one dose) will last about six weeks and Part B (more than
      one dose) will last about eight weeks for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Anticipated">June 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to final follow-up at approximately Day 28</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3478045</measure>
    <time_frame>Baseline up to final follow-up at approximately Day 28</time_frame>
    <description>PK: AUC(0-inf) of LY3478045</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3478045</measure>
    <time_frame>Baseline through final follow-up at approximately Day 28</time_frame>
    <description>PK: Cmax of LY3478045</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3478045 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3478045 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3478045 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3478045 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3478045 + Atorvastatin (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3478045 co-administered with atorvastatin orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo co-administered with atorvastatin orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3478045</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3478045 (Part A)</arm_group_label>
    <arm_group_label>LY3478045 (Part B)</arm_group_label>
    <arm_group_label>LY3478045 + Atorvastatin (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3478045 + Atorvastatin (Part B)</arm_group_label>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy participants as determined through medical history and physical
             examination

          -  Have a body mass index greater than or equal to (≥)18.5 and less than or equal to
             (≤)40 kilograms per square meter (kg/m²)

          -  Have had a stable weight for 3 months prior to screening and enrollment (less than
             [&lt;]5 percent [%] body weight change) and have not received dietary intervention in the
             3 months prior to screening and enrollment

          -  Have safety laboratory test results within the normal reference range for the
             population or investigative site, or results with acceptable deviations that are
             judged as not clinically significant by the investigator

        Exclusion Criteria:

          -  Have a history of fructosuria

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the
             opinion of the investigator, increases the risks associated with participating in the
             study or may confound ECG (QT) data analysis

          -  Have blood pressure greater than (&gt;)160/90 millimeters of mercury (mmHg) and pulse
             rate &lt;50 or &gt;100 beats per minute (bpm), supine (at screening), or with minor
             deviations judged to be acceptable by the investigator

          -  Use of any drugs or substances that are known strong inducers or inhibitors of
             cytochrome P450 (CYP)3A or organic anion-transporting polypeptides (OATPs) are
             specifically excluded within 14 days prior to the first administration of study drug
             and during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>469-513-6727</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

